|
Balance Sheet Cash Flow Statement 8229 Boone Blvd., Ste. 802 Vienna, VA 22182 VA Tel. 703-506-9460 Fax 703-506-9471 |
Type: Public
On the web:
http://www.cel-sci.com
Employees:
30
Employee growth: 15.4%
CEL-SCI hopes to make L.E.A.P.S. and bounds in preventing and treating deadly diseases. Its L.E.A.P.S. (Ligand Epitope Antigen Presentation System) technology modulates T-cells and may lead to synthetic vaccines for herpes, viral encephalitis, smallpox, and other diseases; the National Institutes of Health is testing CEL-1000 (a compound developed using L.E.A.P.S. technology) as a potential avian flu vaccine. The firm's lead drug candidate, however, is Multikine, which might make tumors more susceptible to radiation therapy and help a patient's body produce tumor-fighting antibodies. Multikine is undergoing clinical trials for the treatment of head and neck tumors.
Key numbers for fiscal year ending September, 2008:
Sales: $0.0M
One year growth: (91.1%)
Net income: ($7.7)M
Officers:
CEO, Treasurer, and Director: Geert R. Kersten
President and Director: Maximilian de Clara
SVP Operations and Secretary: Patricia B. Prichep
Competitors:
Celldex Therapeutics
ImClone
Takeda Pharmaceutical
